Literature DB >> 16581405

WHO analysis of causes of maternal death: a systematic review.

Khalid S Khan1, Daniel Wojdyla2, Lale Say3, A Metin Gülmezoglu4, Paul Fa Van Look3.   

Abstract

BACKGROUND: The reduction of maternal deaths is a key international development goal. Evidence-based health policies and programmes aiming to reduce maternal deaths need reliable and valid information. We undertook a systematic review to determine the distribution of causes of maternal deaths.
METHODS: We selected datasets using prespecified criteria, and recorded dataset characteristics, methodological features, and causes of maternal deaths. All analyses were restricted to datasets representative of populations. We analysed joint causes of maternal deaths from datasets reporting at least four major causes (haemorrhage, hypertensive disorders, sepsis, abortion, obstructed labour, ectopic pregnancy, embolism). We examined datasets reporting individual causes of death to investigate the heterogeneity due to methodological features and geographical region and the contribution of haemorrhage, hypertensive disorders, abortion, and sepsis as causes of maternal death at the country level.
FINDINGS: 34 datasets (35,197 maternal deaths) were included in the primary analysis. We recorded wide regional variation in the causes of maternal deaths. Haemorrhage was the leading cause of death in Africa (point estimate 33.9%, range 13.3-43.6; eight datasets, 4508 deaths) and in Asia (30.8%, 5.9-48.5; 11,16 089). In Latin America and the Caribbean, hypertensive disorders were responsible for the most deaths (25.7%, 7.9-52.4; ten, 11,777). Abortion deaths were the highest in Latin America and the Caribbean (12%), which can be as high as 30% of all deaths in some countries in this region. Deaths due to sepsis were higher in Africa (odds ratio 2.71), Asia (1.91), and Latin America and the Caribbean (2.06) than in developed countries.
INTERPRETATION: Haemorrhage and hypertensive disorders are major contributors to maternal deaths in developing countries. These data should inform evidence-based reproductive health-care policies and programmes at regional and national levels. Capacity-strengthening efforts to improve the quality of burden-of-disease studies will further validate future estimates.

Entities:  

Mesh:

Year:  2006        PMID: 16581405     DOI: 10.1016/S0140-6736(06)68397-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  878 in total

1.  Effect of antenatal iodinated contrast agent on neonatal thyroid function.

Authors:  S Rajaram; C E Exley; F Fairlie; S Matthews
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

Review 2.  Active versus expectant management for women in the third stage of labour.

Authors:  Cecily M Begley; Gillian M L Gyte; Declan Devane; William McGuire; Andrew Weeks
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

Review 3.  [Pregnancy and kidney diseases].

Authors:  M Siekierka-Harreis; L C Rump
Journal:  Internist (Berl)       Date:  2011-10       Impact factor: 0.743

Review 4.  Extracellular nucleic acids in maternal circulation as potential biomarkers for placental insufficiency.

Authors:  Ilona Hromadnikova
Journal:  DNA Cell Biol       Date:  2012-02-24       Impact factor: 3.311

5.  What you count is what you target: the implications of maternal death classification for tracking progress towards reducing maternal mortality in developing countries.

Authors:  Suzanne Cross; Jacqueline S Bell; Wendy J Graham
Journal:  Bull World Health Organ       Date:  2009-10-14       Impact factor: 9.408

6.  Heme oxygenase-1 is a potent inhibitor of placental ischemia-mediated endothelin-1 production in cultured human glomerular endothelial cells.

Authors:  Bhavisha A Bakrania; Frank T Spradley; Simon C Satchell; David E Stec; John M Rimoldi; Rama S V Gadepalli; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-12-06       Impact factor: 3.619

7.  Predicting the Risk to Develop Preeclampsia in the First Trimester Combining Promoter Variant -98A/C of LGALS13 (Placental Protein 13), Black Ethnicity, Previous Preeclampsia, Obesity, and Maternal Age.

Authors:  Liora Madar-Shapiro; Ido Karady; Alla Trahtenherts; Argryo Syngelaki; Ranjit Akolekar; Liona Poon; Ruth Cohen; Adi Sharabi-Nov; Berthold Huppertz; Marei Sammar; Kata Juhasz; Nandor Gabor Than; Zoltan Papp; Roberto Romero; Kypros H Nicolaides; Hamutal Meiri
Journal:  Fetal Diagn Ther       Date:  2017-07-21       Impact factor: 2.587

Review 8.  Preeclampsia-eclampsia.

Authors:  Sanjay Gupte; Girija Wagh
Journal:  J Obstet Gynaecol India       Date:  2014-01-31

9.  Assessment of endothelium: Dependent vasodilation with a non-invasive method in patients with preeclampsia compared to normotensive pregnant women.

Authors:  Seyedeh Zahra Allameh; Hatav Ghasemi Tehrani; Seyyed Mohammad Hashemi; Reza Basirat Nia; Forough Hoseini
Journal:  J Res Med Sci       Date:  2014-02       Impact factor: 1.852

Review 10.  Treatment for primary postpartum haemorrhage.

Authors:  Hatem A Mousa; Jennifer Blum; Ghada Abou El Senoun; Haleema Shakur; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2014-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.